Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Infectious Disease
•
Non-Tuberculous Mycobacteria
What alternative treatment regimen do you recommend for patients with Mycobacterium kansasii lung infection who can no longer tolerate ethambutol due to drug toxicities?
Related Questions
What additional treatment strategies would you recommend for a patient with a Mycobacterium chelonae and Mycobacterium abscessus infection following bilateral prophylactic mastectomies and implant insertion, who has undergone multiple surgeries and an extended course of IV antibiotics selected based on sensitivities?
Have you had success treating localized skin infections due to M. chelonae with single agent therapy in immunocompetent hosts?
Would you start treatment for MAC in a patient with nodular bronchiectatic disease who has demonstrated radiographic progression but remains asymptomatic and smear-negative?
Do routinely recommend antifungal prophylaxis for non-transplant patients who have been diagnosed and completed treatment for possible/probable pulmonary aspergillosis and who will need varying degrees of ongoing immunosuppression?
Do you give lifelong anti fungal therapy or a set time period of anti fungal therapy to patients who have vertebral hardware infection with some residual hardware that cannot be removed?
What do you think about chronic suppressive therapy for HSV-2 in a patient with positive antibodies but no prior clinical outbreak?
What infectious differentials should be considered for a patient with intractable erythema nodosum that is non-responsive to acyclovir and steroids?
Do you recommend, based on current evidence, avoiding antimotility agents in patients with non-fulminant C. difficile infection who have no evidence of ileus?
How do you define sepsis in 2024?
What specific criteria or patient conditions would make you hesitant to use fluoroquinolones early in the treatment course for managing MSSA joint infections with oral antibiotics?
